This spontaneous case was reported by a nurse and describes the occurrence of LOCAL REACTION (her first shot she had local reaction to arm) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Cervical spine degeneration, Balance impaired NOS (Impairment of balance), Lumbar disc herniation (Lumbar disc herniation with radiculopathy), Anxiety, Depression, Peptic ulcer disease, Chronic pain, Pruritus, Stress, Iron deficiency anemia, Sinusitis, Premature atrial contraction (PAC (Premature atrial contraction)), Vaginal irritation, Chronic headaches, Peripheral neuropathy, Diastolic dysfunction, Post laminectomy syndrome (Status post lumbar laminectomy), Ventricular fibrillation in September 2012, Compression fracture (Compression fracture of L2 and T11, T12) in December 2015, Tobacco user (Tobacco use: Former smoker) in September 2012, Cellulitis of foot, Upper respiratory disorder (Upper respiratory disease), Cesarean section, Cholecystectomy (Cholecystectomy laproscopic) in August 2008, Appendectomy in April 2009, Stent placement (Coronary artery stent placement RCA) in September 2012, Tubal ligation, Coronary angioplasty and Back surgery (Lower back surgery). Previously administered products included for an unreported indication: PNEUMOCOCCAL VACCINE (Pneumoccocal vaccination) in September 2017, INFLUENZA (Influenza vaccination) on 27-Aug-2020 and TETANUS VACCINE (Tetanus immunization. Less than 10 years). Family history included COPD (Mother dec copd 72), Myocardial infarction (Father dec mi 58), Hyperlipidemia (Sister hyperlipidemia) and Amyloidosis (Brother dec amyloidosis). Concurrent medical conditions included Drug allergy (Asacol (Reaction: Nausea and Vomiting)) since June 2012, Drug allergy (Levaquin "Fluroquinoiones" (Reaction: Local erythema)) since December 2013, Hyperlipidemia, Ulcerative colitis, Hyperglycemia (Elevated glucose/Hyperglycemia), Hypothyroidism (Hypothyroid), COPD (COPD (chronic obstructive pulmonary disease)), Coronary artery disease NOS (CAD (coronary artery disease)) since September 2012 and Alcohol use (Occasional alcohol use). Concomitant products included SULFASALAZINE from 05-Jan-2021 to an unknown date, PREDNISONE from 22-Jan-2021 to an unknown date, OMEPRAZOLE from 15-Dec-2020 to an unknown date, SALBUTAMOL SULFATE (VENTOLIN HFA) from 13-Nov-2020 to an unknown date, ACETYLSALICYLIC ACID (ASPIRIN EC) from 13-Nov-2020 to an unknown date, IRON (IFEREX) from 31-May-2017 to an unknown date, DULOXETINE HCL from 27-Aug-2020 to an unknown date, TRAMADOL HCL from 22-Jan-2021 to an unknown date, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) from 13-Nov-2020 to an unknown date, POTASSIUM CHLORIDE (KLOR-CON M20) from 22-Jan-2021 to an unknown date, FUROSEMIDE from 08-Jan-2020 to an unknown date, LORAZEPAM from 13-Nov-2020 to an unknown date, ATORVASTATIN CALCIUM from 15-Dec-2020 to an unknown date and LEVOTHYROXINE SODIUM (SYNTHROID) from 15-Dec-2020 to an unknown date for an unknown indication.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LOCAL REACTION (her first shot she had local reaction to arm). At the time of the report, LOCAL REACTION (her first shot she had local reaction to arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were reported.   This case was linked to MOD-2021-127126 (Patient Link).